# GutHeart: Targeting Gut Microbiota to Treat Heart Failure

Study · id `cardio:ct-nct02637167` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02637167](<https://clinicaltrials.gov/study/NCT02637167>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02637167

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT02637167. Randomized; no masking; primary purpose treatment. Start 2016-03-11 (registry gives no type); primary completion 2019-06-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT02637167, source copy `cardio:ctgov-nct02637167-2019-03-26`, retrieved 2026-10-26)
- Start date: 2016-03-11 (registry gives no type) (ClinicalTrials.gov record NCT02637167, source copy `cardio:ctgov-nct02637167-2019-03-26`, retrieved 2026-10-26)
- Primary completion: 2019-06-20 (anticipated) (ClinicalTrials.gov record NCT02637167, source copy `cardio:ctgov-nct02637167-2019-03-26`, retrieved 2026-10-26)
- Completion: 2019-12-31 (anticipated) (ClinicalTrials.gov record NCT02637167, source copy `cardio:ctgov-nct02637167-2019-03-26`, retrieved 2026-10-26)
- Countries: Norway (ClinicalTrials.gov record NCT02637167, source copy `cardio:ctgov-nct02637167-2019-03-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02637167-2019-03-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: GutHeart: Targeting Gut Microbiota to Treat Heart Failure
- Condition: Systolic Heart Failure
- Intervention (Drug): Rifaximin
- Intervention (Drug): Saccharomyces boulardii
- Lead sponsor: Oslo University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry lists this organization as the lead sponsor: Oslo University Hospital (`cardio:org-oslo-university-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity (`cardio:pubmed-38331891`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9b9f0382a4197cd6c7f8ef5e6679df8c6cc16de6a79bad81db89c0df3a9574a6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
